StockNews.AI
EXAS
StockNews.AI
181 days

Exact Sciences Announces Fourth Quarter 2024 Results

1. Exact Sciences reported $713 million Q4 revenue, $2.76 billion for 2024. 2. The 2025 outlook remains positive, building on 2024 performance.

Earnings
-1.92%Current Return
VS
-0.39%S&P 500
$50.4802/19 04:22 PM EDTEvent Start
$49.5102/20 10:47 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

Strong revenue growth indicates solid demand, potentially increasing investor confidence.

How important is it?

Positive earnings report and growth outlook are crucial for influencing EXAS stock performance.

Why Long Term?

Sustained revenue momentum could lead to lasting investor interest and stock price increases.

Related Companies

EXASAMGNILMN
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $713 million for the fourth quarter of 2024 and $2.76 billion for the full year of 2024, both ended December 31, 2024. “The Exact Sciences team is off to a good start in 2025, building on the momentum we created in the fourth quarter,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “This year is on track t.

Related News